MUNICH, June 25, 2026 /PRNewswire/ -- Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating adibelivir...
Hence then, the article about innovative molecules announces first patient dosed in phase 2a trial of adibelivir im 250 advancing company into late stage clinical development was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development )
Also on site :
- The memory chip crunch is paying off for this U.S. company
- Amazon's 'Lovely' $96 Foldable Acacia Bench Is Giving 'Charming' Storybook Cottage Energy
- Europe is pushing back on Washington’s chip war